Table 1:
Clinicopathological characteristics of patients
| Variables | N |
|---|---|
| Age, years median (range) | 70 (38–92) |
| Sex, male/female | 238/206 |
| Smoking history (never/ever) | 237/207 |
| Comorbidity and past history | |
| COPD | 73 |
| ILD | 8 |
| Diabetes mellitus | 25 |
| Autoimmune disease | 13 |
| Heart disease | 42 |
| Chronic kidney disease | 10 |
| Cerebrovascular disease | 22 |
| Other malignant tumour | 110 |
| Others | 15 |
| Surgical procedure (Lob/Seg/Wedge) | 333/56/55 |
| Pathological T status (Tis/T1/T2) | 27/351/66 |
| Lymphovascular invasion (absent/present) | 325/119 |
| Visceral pleural invasion (absent/present) | 400/44 |
| Histologic subtype | |
| AIS + MIA | 104 |
| Lepidic | 72 |
| Acinar | 26 |
| Papillary | 177 |
| Micropapillary | 10 |
| Solid | 25 |
| Others | 30 |
| STAS (absent/present) | 309/135 |
| Leucocyte counts, mean ± SD, mm−3 | 5755 ± 1743 |
| Neutrophil counts, mean ± SD, mm−3 | 3505 ± 1310 |
| Monocyte counts, mean ± SD, mm−3 | 330 ± 149 |
| Lymphocyte counts, mean ± SD, mm−3 | 1726 ± 802 |
| LMR, mean ± SD, mm−3 | 5.78 ± 2.75 |
| NLR, mean ± SD, mm−3 | 2.43 ± 2.64 |
| Postoperative adjuvant chemotherapy | 27 |
| Recurrences of lung adenocarcinoma | |
| Local or regional | 25 |
| Distant | 30 |
COPD: chronic obstructive pulmonary disease; ILD, interstitial lung disease; Lob, lobectomy; Seg, segmentectomy; Wedge, wedge resection; STAS, spread through air spaces; LMR, lymphocyte to monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; SD: standard deviation; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma.